COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
9 Citations
73 Claims
-
1-48. -48. (canceled)
-
49. A heterologous chimeric protein comprising:
-
(a) a first domain comprising a portion of CD172a(SIRP1α
) that is capable of binding a CD172a(SIRP1α
) ligand,(b) a second domain comprising a portion of OX40 ligand (OX40L) that is capable of binding an OX40L receptor, and (c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)
-
-
71. A recombinant fusion protein comprising:
-
(a) a first domain comprising a portion of CD172a(SIRP1α
) that is the amino acid sequence of SEQ ID NO;
33 and is capable of binding a CD172a(SIRP1α
) ligand,(b) a second domain comprising a portion of OX40 ligand (OX40L) that is the amino acid sequence of SEQ ID NO;
56 and is capable of binding an OX40L receptor, and(c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain. - View Dependent Claims (72, 73)
-
Specification